BERG named visionary in first-ever Frost Radar AI in Drug Discovery report

13 Apr 2020

The biotech pioneer is one of the first companies to develop corporate partnerships in this application of artificial intelligence (AI) for drug discovery.

BERG, a clinical-stage biotech company that uses AI to research diseases and develop innovative treatments, has been awarded a spot in Frost & Sullivan's first-ever Frost Radar AI in Drug Discovery report in the pharmaceutical industry.

BERG named visionary in first-ever Frost Radar AI in Drug Discovery report

Frost & Sullivan's decision to recognize BERG as a biotech pioneer is based on its strong innovation trajectory, sustained growth over the last decade and being one of the first companies to develop corporate partnerships in this application.

BERG's capabilities also uniquely position the company to apply AI technologies to patient data to better understand the biological drivers of disease.

Amol Jadhav, Industry Analyst, Transformational Health, said: "Their inventive research efforts, understanding of diagnostics and drug development combined with the AI-powered approach have put them at the forefront of precision medicine."

Frost & Sullivan identified BERG as a Visionary in AI drug discovery for a number of reasons:

  • Innovative growth and early adoption of AI analytics has led BERG to powerful partnerships with AstraZeneca, Sanofi Pasteur, Genomics England and the DoD, where various projects from compound discovery to diagnostics and analytics to the development of medication adherence algorithms were completed.
  • The development of the proprietary platform, Interrogative Biology, that utilizes patient health data to identify areas where treatment could be introduced and identifying drug targets.
  • A healthy pipeline in clinical study developments, and currently in phase of clinical validation of its biomarker panel for oncology diagnosis and prognosis in Prostate, Pancreatic Cancer and Parkinson's disease.
  • An expansive portfolio of scientific publications, with over 650 issued in addition to being a leader among its competitors in pending patents.
  • Dr Niven R. Narain, BERG's President and Chief Executive Officer said they will continue to work with partners to identify "what's next" across multiple sectors including oncology, neurology and rare diseases.

    Read More

    Related news

    HKBU scientists develop technique to eliminate drug side effects

    HKBU scientists develop technique to eliminate drug side effects

    19 May 2020

    The novel method paves the way towards the mass production of affordable therapeutic drugs that are made with recyclable materials.

    Read more 
    Vibalogics agrees to additional manufacturing for lead COVID-19 vaccine candidate of J&J unit

    Vibalogics agrees to additional manufacturing for lead COVID-19 vaccine candidate of J&J unit

    18 May 2020

    CDMO is contracted to produce multiple clinical batches from German facility

    Read more 
    Characterizing virus and virus-like particles

    Characterizing virus and virus-like particles

    12 May 2020

    New application study describes the separation and characterisation of adeno associated virus serotypes by AF4.

    Read more 
    AI technology company launches with Novartis and Sarepta deals

    AI technology company launches with Novartis and Sarepta deals

    11 May 2020

    Collaborations focus on gene therapies for serious eye and muscle diseases using Dyno’s CapsidMap artificial intelligence platform to design AAV vectors.

    Read more 
    Bio-Rad launches anti-certolizumab pegol antibodies

    Bio-Rad launches anti-certolizumab pegol antibodies

    5 May 2020

    Using this critical antibody reagent at the preclinical stage of development will minimize the need to revalidate assays with different reagents at the clinical development stage.

    Read more 
    AstraZeneca incredibly excited by lung cancer treatment trial

    AstraZeneca "incredibly excited" by lung cancer treatment trial

    13 Apr 2020

    Independent Data Monitoring Committee (IDMC) recommends unblind Phase III trial of Tagrisso 2 years ahead of schedule.

    Read more 
    German pharma companies are meeting the corona stress test

    German pharma companies are meeting the corona "stress test"

    7 Apr 2020

    The head of the leading German pharmaceutical industry organization says German firms are working top-speed to find coronavirus medications.

    Read more 
    World’s leading biobanks join a global network to advance personalized healthcare research

    World’s leading biobanks join a global network to advance personalized healthcare research

    6 Apr 2020

    The platform enables collaboration between pharmaceutical institutions, healthcare and academic researchers to generate valuable insights and advance medical research.

    Read more 
    Servier strengthens its R&D pipeline with Symphogen acquisition

    Servier strengthens its R&D pipeline with Symphogen acquisition

    6 Apr 2020

    Symphogen becomes the antibody center of excellence within Servier.

    Read more 
    Evotec expands into gene therapy with new Austrian unit

    Evotec expands into gene therapy with new Austrian unit

    6 Apr 2020

    Evotec has established a dedicated gene therapy-based R&D site in Orth an der Donau, Austria with the immediate focus of spearheading a partnership with Japan’s Takeda to support its research projects, the German drug discovery firm said Monday.

    Read more